Invivyd (IVVD) Income from Continuing Operations (2021 - 2025)
Invivyd (IVVD) posted Income from Continuing Operations of 12240000.0 for Q4 2025, down 3.33% on a QoQ basis from 11846000.0 in Q3 2025, and up 33.93% year-over-year from 9139298.67 in Q4 2024.
Invivyd (IVVD) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Invivyd's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 12240000.0 for Q4 2025.
- Quarterly Income from Continuing Operations rose 33.93% year-over-year to 12240000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 56628000.0 (up 73.07% YoY) and the FY2025 annual result came in at 307792000.0, up 26.95% from the prior year.
- Income from Continuing Operations was 12240000.0 for Q4 2025 at Invivyd, down from 11846000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11846000.0 in Q3 2025 and bottomed at 647184000.0 in Q3 2021.
- A 5-year average of 82287400.0 and a median of 51573000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 91.74% in 2022, while the deepest fall reached 186.87% in 2022.
- Invivyd's Income from Continuing Operations stood at 83290000.0 in 2021, then soared by 41.88% to 48412000.0 in 2022, then tumbled by 57.51% to 76256000.0 in 2023, then jumped by 75.71% to 18525000.0 in 2024, then soared by 33.93% to 12240000.0 in 2025.
- Business Quant data shows IVVD's Income from Continuing Operations at 12240000.0 in Q4 2025, 11846000.0 in Q3 2025, and 15420000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Invivyd | 105.07 Mn | -121.62 Mn | 16.07 Mn | -12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | -11.85 Mn |
| Jun 30, 2025 | -15.42 Mn |
| Mar 31, 2025 | -17.12 Mn |
| Dec 31, 2024 | -18.53 Mn |
| Sep 30, 2024 | -62.75 Mn |
| Jun 30, 2024 | -49.68 Mn |
| Mar 31, 2024 | -79.34 Mn |
| Dec 31, 2023 | -76.26 Mn |
| Sep 30, 2023 | -45.04 Mn |
| Jun 30, 2023 | -54.31 Mn |
| Mar 31, 2023 | -39.78 Mn |
| Dec 31, 2022 | -48.41 Mn |
| Sep 30, 2022 | -53.46 Mn |
| Jun 30, 2022 | -58.72 Mn |
| Mar 31, 2022 | -111.33 Mn |
| Dec 31, 2021 | -83.29 Mn |
| Sep 30, 2021 | -647.18 Mn |
| Jun 30, 2021 | -122.23 Mn |
| Mar 31, 2021 | -38.81 Mn |